Should MRI Be Used to Monitor for AS? Con Argument

Posted by Nelson N. Stone, MD | Jul 2018

Nelson N. Stone, MD, presented “Should MRI Be Used to Monitor for AS? Con Argument” during the 23rd Annual Southwest Prostate Cancer Update on April 15, 2018 in Scottsdale, Arizona

How to cite: Stone, Nelson N. “Should MRI Be Used to Monitor for AS? Con Argument” April 15, 2018. Accessed [date today]. https://grandroundsinurology.com/should-mri-be-used-to-monitor-for-as-con-argument/

Should MRI Be Used to Monitor for AS? Con Argument – Summary:

Nelson N. Stone, MD, argues that MRI’s limitations make it insufficient for evaluating and managing prostate cancer patients under consideration for active surveillance (AS) or targeted focal therapy (TFT). Instead, urologists should consider technology like the under-development 3DBiopsy™ system, with a transperineal needle along with mapping software. This approach can detect the precise location of lesions and create a roadmap for treatment planning.

This presentation is a response to “Should MRI Be Used to Monitor for AS? Pro Argument” by Peter A. Pinto, MD.

<script type="application/ld+json">{"@context": "http://schema.org","@type": "VideoObject","name": "Should MRI Be Used to Monitor for AS? Con Argument","description": "Nelson N. Stone, MD, argues that MRI’s limitations make it insufficient for evaluating and managing prostate cancer patients under consideration for active surveillance (AS) or targeted focal therapy (TFT). Instead, urologists should consider technology like the under-development 3DBiopsy™ system, with a transperineal needle along with mapping software. This approach can detect the precise location of lesions and create a roadmap for treatment planning. ","thumbnailUrl": "https://grandroundsinurology.com/wp-content/uploads/2018/07/Should-MRI-Be-Used-to-Monitor-for-AS-Con-copy-2.png","uploadDate": "2018-07-09","duration": "34:27","publisher": { "@type": "Organization", "name": "Grand Rounds in Urology","logo": { "@type": "ImageObject","url": "https://grandroundsinurology.com/wp-content/uploads/2016/11/GRU_WebMedium-e1480706258120.jpg"}},"embedUrl": "https://player.vimeo.com/video/278009759" }</script>

About The Author

Nelson N. Stone, MD

Nelson N. Stone, MD, is Professor of Urology, Radiation Oncology, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai and chief medical officer at Viomerse, Inc. Dr. Stone earned his medical degree from the University of Maryland in 1979. He completed a Residency in General Surgery in 1981 at the University of Maryland, followed by a Residency in Urology at the University of Maryland. He then completed a Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center and a Research Fellowship in Biochemical Endocrinology at Rockefeller University in 1986. He was Chief of Urology at Elmhurst Hospital Queens from 1986-1996. Dr. Stone has founded several medical companies and serves on the editorial board of many scientific journals. He is a member of many professional societies, including the Prostate Conditions Education Council, the Society for Minimally Invasive Therapy, the New York State Urological Society, the American Association of Clinical Urologists, and the American Urologic Association. Dr. Stone has participated in approximately 25 research studies on prostate cancer and has authored more than 500 articles, abstracts, and book chapters, primarily on prostate cancer. He invented the real-time technique for prostate brachytherapy in 1990 and has trained more than 5,000 physicians worldwide through his company ProSeed. His most recent company, Viomerse, creates synthetic body parts (phantoms) for surgical training and has recently released an extended reality remote training platform.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat